Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 19;108(2):403-411.
doi: 10.4269/ajtmh.22-0221. Print 2023 Feb 1.

Prevalence of Poor Quality Ciprofloxacin and Metronidazole Tablets in Three Cities in Cameroon

Christelle Ange Waffo Tchounga  1   2 , Pierre-Yves Sacré  1 , Patient Ciza Hamuli  1   3 , Rose Ngono Mballa  2   4 , Charlotte De Bleye  1 , Eric Ziemons  1 , Philippe Hubert  1 , Roland Marini Djang'eing'a  1
Affiliations

Prevalence of Poor Quality Ciprofloxacin and Metronidazole Tablets in Three Cities in Cameroon

Christelle Ange Waffo Tchounga et al. Am J Trop Med Hyg. .

Abstract

Quality is one of the essential components of medicines and needs to be ensured to preserve the population's health. This can be achieved through post-marketing quality control of medicines and is one of the most important duties of national regulatory authorities. In collaboration with the Cameroonian National Drug Quality Control and Valuation Laboratory, the decision was made to initiate a prevalence study to assess the quality of antiinfective medicines in Cameroon. A total of 150 samples of ciprofloxacin tablets and 142 samples of metronidazole tablets were collected from 76 licensed pharmacies and 75 informal vendors in three cities in Cameroon using a random strategy wherever possible and a mystery shopper approach. Three tests were carried out on each of the samples. Visual inspection allowed to find two falsified samples (0.7%) due to lack of information about the manufacturing company, and five more samples (1.7%) were deemed to be substandard due to flaws in the product. An additional 13 samples (4.5%) failed disintegration testing, and six (2.1%) others failed high-performance liquid chromatography assay testing due to insufficient active pharmaceutical ingredient (API) content. All samples were found to contain some API. A prevalence of 7.9% substandard or falsified (SF) medicines was found. Moreover, the prevalence of outlets selling SF medicines was greater in the informal sector (26.7%) than in the formal sector (2.6%). Although the prevalence of SF medicines found was low, efforts need to be made by national regulatory authorities to monitor the pharmaceutical market more closely.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Geographic location of sampling sites in Cameroon.
Figure 2.
Figure 2.
Distribution of samples according to stated country of origin.
Figure 3.
Figure 3.
(A) Assay results of ciprofloxacin samples. (B) Assay results of metronidazole samples.
See this image and copyright information in PMC

References

    1. UN Human Rights, Office of the High Commissioner Access to Medicines and the Right to Health. Available at: https://www.ohchr.org/en/development/access-medicines-fundamental-elemen.... Accessed May 3, 2022.
    1. Bassat Q, Tanner M, Guerin PJ, Stricker K, Hamed K, 2016. Combating poor-quality anti-malarial medicines: a call to action. Malar J 15: 302. - PMC - PubMed
    1. Green MD, Hostetler DM, Nettey H, Swamidoss I, Ranieri N, Newton PN, 2015. Integration of novel low-cost colorimetric, laser photometric, and visual fluorescent techniques for rapid identification of falsified medicines in resource-poor areas: application to artemether–lumefantrine. Am J Trop Med Hyg 92 (Suppl 6): 8–16. - PMC - PubMed
    1. World Health Organization , 2013. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020. Available at: https://www.who.int/publications/i/item/9789241506236. Accessed April 20, 2022.
    1. World Health Organization , 2017. A Study on the Public Health and Socioeconomic Impact of Substandard and Falsified Medical Products. Available at: https://www.who.int/publications/i/item/9789241513432. Accessed May 3, 2022.